Topical Mebo Versus Lidocane in Healing Time of Traumatic Oral Ulcer

October 6 University

Status: Completed

Conditions: Mebo; Lidocaine; Traumatic Oral Ulceration; Healing

Treatments: Drug: MEBO; Drug: Lidocaine

Study type: Interventional

Funder types: Other

Identifiers

NCT06184282

RECO6U/15-2023

Details and patient eligibility

About

This study aims to assess topical MEBO application on pain relief and wound healing.

Full description

One of the conditions that affect the mouth frequently is a traumatic ulcer. Between 3 and 24 % of the population are affected, which is a significant prevalence. It is symptomatic to treat traumatized ulcers. Oral wound healing is a dynamic process and complicated phenomenon involving secondary concerns, a succession of overlapping stages of rebuilding cell and tissue structure.

Inflammation, granulation tissue creation, matrix formation, re-epithelialization, and tissue remodeling are some of the cellular and physiological activities that occur during wound healing.

Oral wound healing is a dynamic process and complex phenomenon involving secondary issues, series overlapping stages of restoring tissue and cellular structures.

Since 1995, the Moist Exposed Burn Ointment (MEBO), a Chinese burn ointment, has had a recognized US patent. Beta-sitosterol, Phellodendron amurense, Scutellaria baicalensis, Coptis chinensis, Pheretima aspergillum, Beeswax, and sesame oil are all natural ingredients found in MEBO, a pure herbal extract.

Enrollment: 28 patients

Sex: All

Ages: 20 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age from 20 to 50 years.
• Both sexes.
• Systemically healthy patients.
• Patients with good oral hygiene.

Exclusion criteria

• Patients with any uncontrolled local or systemic disease.
• Smokers.
• Pregnancy and lactation.
• Patients allergic to the used agents.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

28 participants in 2 patient groups

MEBO group

Experimental group

Description:

MEBO (Julphar®, Ras Al Khaimah, United Arab Emirates) was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.

Treatment:

Drug: MEBO

Control Group

Active Comparator group

Description:

Lidocaine gel was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.

Treatment:

Drug: Lidocaine